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Evolution and Protection of Cerebral
Infarction Evaluated by PET and SPECT
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Abstract Since cerebral infarction results from a reduction of cerebral blood flow
(CBF) by the occlusion or stenosis of carotid or intracranial arteries, CBF is a
primary parameter to predict of ischemic brain injury. Single-photon emission
tomography (SPECT) and positron emission tomography (PET) contributed to
evaluate loss of cerebral autoregulation, uncoupling state between CBF and brain
metabolism, and ischemic penumbra. Measurement of CBF and oxygen meta-
bolism by 15O PET revealed the process of infarct growth in hyperacute stage of
cerebral infarction and areas with depressed oxygen metabolism, but normal water
diffusion in magnetic resonance imaging (MRI) was termed as “metabolic penum-
bra.” Recently, some researchers shed light on the role of glial cells in the energy
metabolism of the brain and 11C-acetate PET and demonstrated that astrocytic
energy metabolism in TCA cycle was protective against ischemia. SPECT and
PET studies for secondary reaction after ischemia (i.e., selective neuronal loss by
123I-iomazenil SPECT and 11C-flumazenil PET, tissue hypoxia by 18F-FMISO
PET, and neuroinflammation by TSPO-PET) are expected as new biomarkers.
Combining these imaging biomarkers with classical CBF measurement may contri-
bute to develop innovative drugs for pharmacological neuroprotection in the ther-
apy of cerebral infarction.
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19.1 Introduction
Cerebral infarction results from a reduction in cerebral blood flow (CBF) arising
from the occlusion or stenosis of carotid or intracranial arteries, and the progression
of this event typically ends with the necrosis of various brain tissue components,
including neurons. Since tissue damage varies according to the severity of brain
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ischemia, CBF is a primary parameter for predicting the extent of ischemic brain
injury.
Positron emission tomography (PET) and single-photon emission computed
tomography (SPECT) have contributed to the elucidation of the disease process
responsible for brain ischemia from an acute to chronic stage. PET studies have
mainly measured CBF and oxygen metabolism but have been expanded to include
the detection of neuronal loss, tissue hypoxia, and neuroinflammation. Quantitative
15O PET measurements can provide information on CBF, the cerebral metabolic
rate of oxygen (CMRO2), the cerebral blood volume (CBV), and the oxygen extrac-
tion fraction (OEF), and these parameters enable impaired cerebral autoregulation
and the uncoupling of perfusion and metabolism to be diagnosed based on absolute
values. The SPECT studies can visualize the magnitude and extent of ischemia in a
clinical setting. Neurons are more vulnerable than other cell groups in the brain, and
selective neuronal loss sometimes occurs in patients with mild to moderate brain
ischemia. PET and SPECT are advantageous for demonstrating this type of brain
injury, which cannot be visualized by comparing computed tomography (CT) and
magnetic resonance imaging (MRI) findings. PET imaging of tissue hypoxia is
expected to distinguish permanent and temporal ischemic areas surrounding the
ischemic core. Translocator protein (TSPO) PET can represent neuroinflammation
in areas with evolving infarcts and may become a biomarker for neuroprotective
therapy. Recently, important roles of astrocytes in the energy metabolism of the
brain have been reported. The imaging of astrocytes using 11C-acetate PET may
provide a sensitive marker for evaluating glial metabolism in the ischemic brain.
The purpose of using these imaging probes depends on the course or stage of
Fig. 19.1 Time course of infarct evolution and related PET/SPECT imaging
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cerebral infarction (Fig. 19.1). In this chapter, we introduce the use of PET and
SPECT imaging in studies to clarify the process of cerebral infarction.
19.2 Perfusion and Oxygen Metabolism in Brain Ischemia
CBF is a key parameter of ischemic brain damage that can be quantitatively
measured using PET and SPECT. A decrease in the cerebral perfusion pressure
(CPP) induces primary damage to the supply of oxygen and energy substance to the
brain. Protective mechanisms against reductions in the CPP can be evaluated using
PET and SPECT. The first mechanism is “cerebral autoregulation,” the origin of
which is cardiac pump function. CBF is constant within a mean arterial blood
pressure (MABP) range of 60–160 mmHg [1]. To maintain a constant CBF,
cerebral precapillary arterioles can dilate when the CPP decreases and can constrict
when the CPP increases. Although this mechanism of dilation and constriction for
cerebral autoregulation remains unclear, recent studies have indicated that CBF
control is initiated in the cerebral capillaries, where pericytes can constrict capil-
laries in response to the effect of noradrenaline [2]. Cerebral autoregulation is
disturbed by brain ischemia [3], and its capacity can be estimated using the cerebral
vasoreactivity (CVR) to the change in the arterial partial pressure of carbon dioxide
(PaCO2). In SPECT studies, acetazolamide, which is another vasodilating agent, is
used to test CVR. A reduced CVR in patients with steno-occlusive carotid artery
disease is a major predictor of stroke recurrence [4, 5].
By combining this information with data on CBF and oxygen metabolism
measured using 15O PET, we can evaluate other protective states against CPP
reduction (Fig. 19.2). When cerebral autoregulation is functioning well, CBF
remains normal and the CBV increases, indicating the dilatation of collateral
vessels. When the CPP is reduced beyond the point of compensation by vaso-
dilatation, the cerebral autoregulation is exhausted and the CBF begins to decrease.
Fig. 19.2 15O PET images in a patient with right carotid and MCA occlusion. PET images of (a)
CBF, (b) CBV, (c) CPP, and (d) OEF. The CPP images were created by dividing CBF and CBV.
The area with a severe CPP reduction corresponded to the area with an elevated OEF (misery
perfusion)
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When CMRO2 is preserved, then the OEF starts to increase. Such increases in the
OEF are known as “misery perfusion” and can be observed during the acute stage of
cerebral infarction (Fig. 19.3). In the chronic stage of cerebral infarction, misery
perfusion in patients with unilateral carotid artery occlusion suggests a high prob-
ability of stroke recurrence [6–8]. Powers et al. classified the severity of cerebral
ischemia from Stage 0 to Stage II according to CBF, CBV, and OEF [9]. Stage II is
equal to the state of misery perfusion. The 5-year stroke recurrence rate for Stage II
patients with unilateral steno-occlusive internal carotid artery (ICA) was 70 %,
whereas it was 20 % for Stage 0 and I patients [8].
19.3 Infarct Growth in Acute Cerebral Infarction
The ischemic threshold of CBF has been thoroughly evaluated in both experimental
studies and clinical studies. Symon and colleagues revealed a relationship between
CBF, neurological deficits, and tissue damage in baboon models of cerebral ische-
mia [10]. They showed that the electric activity of somatosensory evoked potentials
in cerebral tissue was preserved at a CBF above 20 mL/100 g/min (40 % of normal
level), whereas it was impaired when the CBF decreased to 10–20 mL/100 g/min.
Fig. 19.3 Misery perfusion in a patient with acute left MCA occlusion. PET images of (a) CBF,
(b) CMRO2, (c) OEF, and (d) CBV examined on the day of stroke onset. The CBF in the left MCA
territory reduced, whereas the CMRO2 in the corresponding area was relatively preserved. The
OEF was elevated in the same area, indicating an uncoupled state between perfusion and oxygen
metabolism (misery perfusion). A CT image obtained on the same day (e) did not show any
morphological changes
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Although this impaired electric activity was reversible by recirculation, irreversible
damage resulting from an elevated extracellular potassium concentration and sub-
sequent cell death occurred when the CBF was reduced to less than 6–10 mL/100 g/
min. Astrup, Siesjo, and Symon defined the ischemic penumbra as brain tissue with
CBF thresholds between electric (20 mL/100 g/min) and membrane failure
(6–10 mL/100 g/min) [11]. In a baboon model, Jones et al. found that a longer
period of ischemia was associated with a higher threshold for membrane failure
[12]. Their studies indicated that the ischemic penumbra should be restored as early
as possible to reduce the volume of cerebral infarction. Clinical SPECT studies
have demonstrated the validity of evaluating the ischemic threshold during the
acute stage of infarction. Shimosegawa et al. evaluated SPECT images within 6 h of
onset in ischemic stroke patients and revealed that a CBF of less than 30–50 % of
that in unaffected brain regions was capable of inducing cerebral infarction [13]
(Fig. 19.4). When the CBF was less than 20 % of that in the unaffected hemisphere,
the probability of hemorrhagic infarction after recanalization therapy
increased [14].
Although the CBF threshold has been established in both experimental and
clinical studies, the metabolic threshold and its relation to the development of
infarction has not yet been clarified. In a 15O PET study of patients with cerebral
infarction where imaging was performed within 6 h of onset, Shimosegawa
et al. demonstrated that infarct growth occurred in brain lesions with a depressed
CMRO2 but normal water diffusion on diffusion-weighted imaging (DWI) [15]
(Fig. 19.5). Peri-infarct areas with a CMRO2 of less than 45–62 % of that in
unaffected brain regions on the initial 15O PET showed volume expansion of the
brain infarction at 3 days after onset, and they named this phenomenon “metabolic
penumbra.” The normal diffusion in these areas indicated that adenosine triphos-
phate (ATP) synthesis was still preserved to a degree sufficient to maintain an
Fig. 19.4 Prediction of cerebral infarction by acute CBF-SPECT. A diffusion-weighted MR
image obtained at 1.3 h after onset (a) demonstrated only a small lesion in the frontal lobe. A
99mHMPAO-SPECT image obtained at 2.3 h after onset (b) showed a broad reduction in CBF in
the left cerebral hemisphere. A CBF reduction of more than 50 %, compared with the contralateral
region, was observed in the left frontal lobe, and this area progressed into a complete infarction
visible on a CT image obtained 4 days after onset (c)
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ATP-dependent neuronal membrane ion pump in the area of the evolving infarct as
early as 6 h after onset. Therefore, a metabolic penumbra with a moderate decrease
in CMRO2would be a critical treatment target, using early reperfusion and pharmaco-
logical neuroprotection to reduce the volume expansion of the brain infarction.
19.4 Role of Astrocytic Function in Brain Ischemia
Recently, some researchers have shed light on the role of glial cells in energy
metabolism in the brain. Glutamate is a major excitatory neurotransmitter of the
brain, and glutamate in the synaptic cleft is removed by astrocytes surrounding
glutaminergic synapses. The removed glutamate is converted into glutamine in
astrocytes by glutamine synthetase. Glutamine is released by astrocytes and taken
Fig. 19.5 Metabolic penumbra in acute brain infarction. (a) DWI of MRI obtained 4 h after onset,
(b) perfusion-weighted image (PWI) obtained 4 h after onset, (c) DWI obtained 3 days after onset,
(d) CBF obtained 3 h after onset, (e) CMRO2 obtained 3 h after onset, and (f) OEF obtained 3 h of
onset in a patient with right ICA embolic occlusion. An MRI examination indicated PWI–DWI
mismatch in the territory of the right ICA. DWI on day 3 indicated an evolution of the infarction
within the mismatch. The initial PET examination indicated that the PWI–DWI mismatch lesion
exhibited reductions in CBF and CMRO2 associated with misery perfusion (increased OEF, white
arrow). The PWI–DWI mismatch corresponded to suppressed energy metabolism that was still
higher than the threshold for ion pump failure (Reprinted from Brain Mapping: An Encyclopedic
Reference, Vol. 3/1st edition, Arthur W. Toga (Editor in Chief), Hemodynamic and Metabolic
Disturbances in Acute Cerebral Infarction (title)/Clinical Brain Mapping (chapter), written by
E. Shimosegawa, p. 829–838, 2015, with permission from Elsevier)
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up by neuronal terminals, where it is enzymatically reconverted to glutamate and
stored in the neurotransmitter pool for the next transmission. This process is called
“glutamate-glutamine cycle” and requires ATP [16]. Furthermore, astrocytes play
an important role in glycolysis in the brain. Activation by the glutamate transporter
on the astrocytic membrane stimulates glucose uptake into astrocytes. This glucose
is processed glycolytically, resulting in the release of lactate as an energy substrate
for neurons. Lactate produced by this process is transferred to neurons for oxidation
(the astrocyte-neuron lactate shuttle: ANLS) [17]. This lactate produces two ATP
molecules, which contribute to the Na-K ion pump function and the synthesis of
glutamine from glutamate. In ischemic brain where ATP synthesis is restricted, the
conversion of glutamate in the synaptic cleft is disturbed. Continuous stimulation
by glutamate induces an influx of Ca2+ ion, resulting in anoxic depolarization, and
leads to inflammation and apoptosis. Therefore, the glutamate-glutamine cycle and
ANLS are deeply related to astrocytic function and plays a critical role in the
evolution from penumbra to infarction.
For the specific imaging of astrocyte, acetate is expected to be useful as a
selective marker of astrocytic energy metabolism [18, 19]. 14C-acetate is rapidly
incorporated into glutamine via glutamate by glutamine synthetase localized in
astrocytic cells [20]. Hosoi et al. demonstrated that 14C-acetate uptake is dramat-
ically decreased in a 3-min ischemia and reperfusion model, indicating that the
metabolic and functional impairment of astrocytes continues after the restoration of
CBF [21]. 11C-labeled acetate could be a promising PET tracer for the evaluation of
astrocytic metabolism in human studies (Fig. 19.6).
Fig. 19.6 Qualitative and quantitative 11C-acetate PET imaging for astrocytic energy metabolism.
(a) An averaged 11C-acetate PET image (from 0 to 40 min) and (b) an averaged Kmono image in a
healthy volunteer. The energy metabolism evaluated using the Kmono image was different from
the normal oxygen metabolism evaluated using the CMRO2 image (c)
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19.5 Selective Neuronal Loss in Ischemic Brain Injury
Tissue vulnerability differs among neurons, glial cells, and blood vessels. Selective
neuronal necrosis is known to occur in neuron-specific ischemic injury, where other
cell components are preserved, and is associated with the expression of apoptosis-
related DNA damages and repair genes [22]. In PET and SPECT imaging, 11C-
flumazenil and 123I-iomazenil are considered to be neuron-specific tracers that bind
central benzodiazepine receptors that are specifically localized on the membranes
of cortical neurons. Preserved 11C-flumazenil accumulation in acute ischemic brain
can predict the probability of surviving an infarct [23, 24]. Hatazawa
et al. examined 123I-iomazenil SPECT in patients with cortical and subcortical
infarction. They reported a patient with global aphasia who had a purely subcortical
infarction and significantly diminished 123I-iomazenil uptake in CT-negative Broca
and Wernicke areas [25]. This result indicated that 123I-iomazenil SPECT could
sensitively detect lesions responsible for clinical symptoms, compared with morpho-
logical examinations (Fig. 19.7).
19.6 Detection of Tissue Hypoxia
Tissue hypoxia can be visualized using 18F-labeled nitroimidazole derivatives or
62/64Cu-labeled lipophilic chelate compounds. 18F-fluoromisonidazole (18F-FMISO)
PET is a representative hypoxic marker. Under hypoxic conditions, 18F-FMISO
Fig. 19.7 Selective neuronal loss: (a) T2-weighted image (T2WI) in a patient with subcortical
infarction of the left putamen 1.5 months after onset, (b) CBF image of the corresponding slice
obtained by 123I-IMP SPECT, and (c) 123I-iomazenil SPECT image of the corresponding slice. The
MR image showed no obvious lesion in the left cortical area, whereas 123I-iomazenil SPECT
demonstrated a decrease in accumulation (white arrow), indicating selective neuronal loss. The
CBF reduction extended beyond the cortical areas of 123I-iomazenil reduction (Reprinted from
Brain Mapping: An Encyclopedic Reference, Vol. 3/1st edition, Arthur W. Toga (Editor in Chief),
Hemodynamic and Metabolic Disturbances in Acute Cerebral Infarction (title)/Clinical Brain
Mapping (chapter), written by E. Shimosegawa, p. 829–838, 2015, with permission from Elsevier)
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passively diffuses into cells and is reduced by nitroreductase enzymes and trapped
by intracellular molecules. The retention of 18F-FMISO is inversely proportional to
the tissue partial pressure of O2. Takasawa et al. revealed that the selective accumu-
lation of 18F-FMISO was found in permanent and temporal ischemic areas sur-
rounding the ischemic core [26]. They demonstrated that 18F-FMISO uptake in the
ischemic brain was only elevated during the early phase of middle cerebral artery
(MCA) occlusion. After early reperfusion, no demonstrable tracer retention was
observed. In patients with an acute MCA territory stroke, Markus et al. reported that
18F-FMISO PET showed the temporal evolution of tissue hypoxia [27]. A higher
hypoxic volume was observed in the core of the infarct within 6 h of onset, and the
location moved to the periphery or external to the infarct at later time points. They
also showed that tissue without 18F-FMISO uptake within the final infarct was
presumed to have infarcted by the time of the acute 18F-FMISO PET. These experi-
mental and clinical results are very interesting because they suggested that 18F-
FMISO uptake changes continuously during the course of brain infarction. Since
18F-FMISO PET is unable to discriminate between complete infarcted area and
non-hypoxic viable tissue during the acute stage of infarction, the timing of the PET
examination is likely to be critical for diagnosing whether the tissue is salvageable.
19.7 Imaging of Neuroinflammation
In focal brain ischemia, inflammatory reactions mainly occur in the peri-infarct area
and lead to an overexpression of peripheral benzodiazepine receptors (PBR)/18-
kDa TSPO on the membrane of activated microglia, macrophages, and activated
astrocytes. Several PET tracers that specifically bind to TSPO have been developed
as biomarkers of neuroinflammation. Imaizumi et al. demonstrated that 11C-PBR28
accumulated in the peri-infarct lesions of a rat ischemia model, indicating that
neuroinflammation does not occur in the ischemic core but in penumbral lesions
[28]. In our preclinical study using a temporary MCA occlusion model, 11C-DPA-
713 uptake increased in the area surrounding the infarct core after 4 days of
ischemia, where the expression of microglia/macrophages was positive using
CD11b immunostaining (Fig. 19.8). In an impressive study, Martı´n et al. reported
that 18F-DPA-714 uptake decreased at 7 days after cerebral ischemia in rats treated
with minocycline, compared with saline-treated animals [29]. Whether the
increased regional microglia/macrophage activation visualized by TSPO PET is a
good biomarker remains controversial. TSPO molecular imaging, however, might
have diagnostic potential for assessing therapeutic strategies, such as the use of
neuroprotective or anti-inflammatory drugs during the acute or subacute stage of
cerebral infarction.
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19.8 Summary
Measurements of hemodynamic and metabolic disturbances using PET and SPECT
have been utilized to study the acute and chronic stages of cerebral infarction. CBF,
CMRO2, CBV, OEF, and CVR are basic parameters for estimating CPP reduction.
An acute metabolic penumbra (decreased CMRO2 in peri-infarct area on initial
PET) and misery perfusion (areas with decreased CBF with maintained CMRO2 in
ischemic brain) during the acute and chronic stages are indicators of evolving
infarction. Astrocytes have a protective role against cerebral infarction by reducing
the glutamate concentration during ischemia, and 11C-acetate PET may provide
information regarding glial cell function. Neuron-specific imaging can only be
performed using PET and SPECT, and it would be useful to collate the clinical
symptoms with neuronal damage. PET tracers for tissue hypoxia and neuro-
inflammation have been developed and are promising biomarkers for detecting
infarct growth and salvageable tissue and are expected to become useful as probes
in future therapeutic interventions.
Fig. 19.8 TSPO PET image of rat ischemic model. (a) 11C-DPA713 PET and (b) the corres-
ponding CD11b immunostaining image. 11C-DPA713 accumulated in the peripheral region of the
ischemic core at 4 days after 60 min of MCA occlusion and reperfusion (white arrows). The
CD11b-positive findings agreed with the uptake of 11C-DPA713 (white arrow heads), indicating
that macrophages/microglia were activated by neuroinflammation after brain ischemia
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